Prilenia is a clinical stage biotech company, led by Michael Hayden, MD, PhD., together with a highly experienced team with a track record of success.
Michael is a world-renowned scientist in Huntington Disease research. He is the former President of Global R&D and Chief Scientific Officer at Teva Pharmaceuticals, where he led the development of ~35 new products towards approval in several major markets, predominantly in CNS.


The company has recently raised $68.5M in a Series A financing round to launch the planned HD and ALS late-stage clinical trials. The funding round was led by Forbion, and accompanied by Morningside Venture Investments, Sectoral Asset Management, Talisman Capital Partners and ALS Investment Fund. All of which are leading Venture Capital firms in the Life Science field.


Pridopidine, the company’s lead asset, is a highly selective sigma-1 receptor (S1R) agonist with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children.


Pridopidine has been shown to maintain functional capacity in early HD patients, as measured by Total Functional Capacity (TFC). Furthermore, it was recently selected from an international competition of over 30 potential therapeutics for inclusion in the first ever ALS platform trial, led by the Healey Center for ALS at Massachusetts General Hospital. Pridopidine is currently in late-stage clinical development for HD and ALS. Both trials, the global phase 3 clinical trial in HD and the platform trial in ALS are currently active and recruiting. In the face of compelling results these trials could potentially lead to the registration of pridopidine for these indications. 

Prilenia Therapeutics partner - Forbion logo
Prilenia Therapeutics partner - Talisman logo
Prilenia Therapeutics partner - Sectoral asset management logo
Prilenia Therapeutics partner - ALS IF Logo